Thrombosis with Thrombocytopenia Syndrome (TTS), also known as Vaccine-induced Immune…
More Content Here
Thrombosis with Thrombocytopenia Syndrome (TTS), also known as Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), is a very rare syndrome. It involves the development of blood clots (thrombosis) along with a low platelet count (thrombocytopenia).
Here's a detailed breakdown:
What is it?
• TTS is characterized by two main components:
o Thrombosis: Formation of blood clots that can block blood flow in various parts of the body.
o Thrombocytopenia: A condition where there's a decrease in the number of platelets in the blood. Platelets are essential for normal blood clotting and preventing excessive bleeding.
• TTS typically occurs 4 to 42 days after receiving specific COVID-19 vaccines, particularly those using adenoviral vector technology, such as AstraZeneca and Johnson & Johnson vaccines.
Causes
The exact cause of TTS is still under investigation. However, it's believed to be an immune response triggered by the vaccine. The adenoviral vector in these vaccines might lead to the development of antibodies that mistakenly attack platelets, causing their destruction and contributing to blood clot formation.
Symptoms
While TTS is rare, being aware of the symptoms is crucial for early diagnosis and treatment. Here are some key signs to watch for:
• Severe or persistent headaches
• Blurred vision or vision changes
• Shortness of breath
• Chest pain
• Leg swelling or pain
• Persistent abdominal pain
• Easy bruising or tiny blood spots under the skin (not at the injection site)
Treatment
Early diagnosis and treatment are essential for improving outcomes in TTS. Treatment typically involves:
• Medications to prevent further blood clots: This may include anticoagulants like heparin (with caution due to potential complications) or direct oral anticoagulants (DOACs).
• Immunotherapy: Medications like corticosteroids or intravenous immune globulin (IVIG) may be used to suppress the abnormal immune response.
• Platelet transfusion: In some cases, if the platelet count is very low, a platelet transfusion might be necessary.
Prevention
The risk of TTS is significantly lower than the dangers of COVID-19 itself. Here's what to consider:
• Vaccination recommendations: Several countries have limited the use of adenoviral vector vaccines due to the TTS risk.
• Consultation with your doctor: If you have a history of blood clots or low platelet count, discuss your individual risk and appropriate COVID-19 vaccination options with your doctor.
• Awareness of symptoms: Be aware of the potential symptoms of TTS and seek immediate medical attention if you experience any of them following COVID-19 vaccination.
Additional Resources
• The American Society of Hematology: Vaccine-induced Immune Thrombotic Thrombocytopenia: https://ashpublications.org/blood/article/138/4/293/476045/Vaccine-induced-immune-thrombotic-thrombocytopenia
• The Melbourne Vaccine Education Centre: Thrombosis with thrombocytopenia syndrome (TTS): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552386/
• Healthdirect Australia: Thrombosis with thrombocytopenia syndrome (TTS): https://www.health.gov.au/our-work/covid-19-vaccines/advice-for-providers/clinical-guidance/tts
